For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Intellia Therapeutics Inc (NASDAQ: NTLA) was $8.88 for the day, up 1.02% from the previous closing price of $8.79. In other words, the price has increased by $1.02 from its previous closing price. On the day, 3.35 million shares were traded. NTLA stock price reached its highest trading level at $9.16 during the session, while it also had its lowest trading level at $8.74.
Ratios:
Our analysis of NTLA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.21 and its Current Ratio is at 6.21. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.09.
On November 11, 2025, Evercore ISI Downgraded its rating to In-line which previously was Outperform but kept the price unchanged to $8.
JP Morgan Downgraded its Neutral to Underweight on November 07, 2025, while the target price for the stock was maintained at $5.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 11 ’25 when LEONARD JOHN M sold 88,146 shares for $9.49 per share. The transaction valued at 836,384 led to the insider holds 1,038,928 shares of the business.
LEONARD JOHN M bought 88,146 shares of NTLA for $822,402 on Dec 11 ’25. On Oct 01 ’25, another insider, Schultes Birgit C, who serves as the EVP, Chief Scientific Officer of the company, sold 31 shares for $17.38 each. As a result, the insider received 539 and left with 105,184 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 1028569792 and an Enterprise Value of 615491712. For the stock, the TTM Price-to-Sale (P/S) ratio is 17.70 while its Price-to-Book (P/B) ratio in mrq is 1.37. Its current Enterprise Value per Revenue stands at 10.699 whereas that against EBITDA is -1.313.
Stock Price History:
The Beta on a monthly basis for NTLA is 2.05, which has changed by -0.27832514 over the last 52 weeks, in comparison to a change of 0.13329959 over the same period for the S&P500. Over the past 52 weeks, NTLA has reached a high of $28.25, while it has fallen to a 52-week low of $5.90. The 50-Day Moving Average of the stock is -34.88%, while the 200-Day Moving Average is calculated to be -21.64%.
Shares Statistics:
NTLA traded an average of 7.79M shares per day over the past three months and 3551480 shares per day over the past ten days. A total of 115.79M shares are outstanding, with a floating share count of 110.34M. Insiders hold about 4.74% of the company’s shares, while institutions hold 86.29% stake in the company. Shares short for NTLA as of 1764288000 were 44572813 with a Short Ratio of 5.72, compared to 1761868800 on 39075621. Therefore, it implies a Short% of Shares Outstanding of 44572813 and a Short% of Float of 43.169999999999995.
Earnings Estimates
. The current assessment of Intellia Therapeutics Inc (NTLA) involves the perspectives of 18.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.99, with high estimates of -$0.89 and low estimates of -$1.07.
Analysts are recommending an EPS of between -$3.8 and -$4.11 for the fiscal current year, implying an average EPS of -$3.97. EPS for the following year is -$3.59, with 21.0 analysts recommending between -$1.96 and -$4.41.
Revenue Estimates
A total of 22 analysts have provided revenue estimates for NTLA’s current fiscal year. The highest revenue estimate was $68.3M, while the lowest revenue estimate was $44.65M, resulting in an average revenue estimate of $56.86M. In the same quarter a year ago, actual revenue was $57.88M
